Evidence map›Paper›PMID 36186916›Full record

ArticleTechniques in orthopaedics (Rockville, Md.)2018

Molecular Targeted Therapy Approach to Musculoskeletal Tumors.

Izuchukwu Ibe, Monique Haynes, Andrew Koo, Dieter Lindskog, Gary E Friedlaender, Francis Y Lee

Open access · greenAbstract read
In one paragraph

Article in Techniques in orthopaedics (Rockville, Md.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Izuchukwu IbeDepartment of Orthopaedics and Rehabilitation, Yale University School of Medicine, Center for Musculoskeletal Care, Yale New Haven Hospital, New Haven, CT.
Monique HaynesDepartment of Orthopaedics and Rehabilitation, Yale University School of Medicine, Center for Musculoskeletal Care, Yale New Haven Hospital, New Haven, CT.
Andrew KooDepartment of Orthopaedics and Rehabilitation, Yale University School of Medicine, Center for Musculoskeletal Care, Yale New Haven Hospital, New Haven, CT.
Dieter LindskogDepartment of Orthopaedics and Rehabilitation, Yale University School of Medicine, Center for Musculoskeletal Care, Yale New Haven Hospital, New Haven, CT.
Gary E FriedlaenderDepartment of Orthopaedics and Rehabilitation, Yale University School of Medicine, Center for Musculoskeletal Care, Yale New Haven Hospital, New Haven, CT.
Francis Y LeeDepartment of Orthopaedics and Rehabilitation, Yale University School of Medicine, Center for Musculoskeletal Care, Yale New Haven Hospital, New Haven, CT.
Yale New Haven Hospital · USYale University · US

Funding

ERK Signaling in Inflammatory Bone LossR01AR056246 · NIAMS · YALE UNIVERSITY · PI LEE, FRANCIS YOUNG-IN · 2009 to 2018
$3.5M
Bone and Breast Cancer Molecular InteractionsR01CA203011 · NCI · YALE UNIVERSITY · PI LEE, FRANCIS YOUNG-IN · 2016 to 2020
$2.3M
NCI NIH HHS R01 CA203011NIAMS NIH HHS R01 AR056246
6 · The paper itself

Abstract

The future of cancer treatment is promising. Although marred by years of plateau in outcomes, new avenues have been identified that are poised to change how we treat cancer. Molecular targeted therapy or targeted therapy is one of these methods. Molecular targeted therapy involves identifying specific pathways or markers that allow cancer cells to flourish. Once identified, specific molecules can be used to block proliferative pathways, thereby negatively impacting tumor growth. Targeting specific pathways that prolong the survival of the cancer cell can lead to a decreased cancer burden, and improved patient outcomes. This article reviews the tenets of molecular targeted therapy, common pathways, target acquisition for drug development, and the pathways that have been elucidated in musculoskeletal tumors.

Identifiers

PMID36186916
PMCPMC9524233
OpenAlexW2795343659

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.